BURNABY, BC, Aug. 7 /CNW/ - Welichem Biotech Inc. ("WBI" or the
"Company") (TSX-V: WBI) is very pleased to announce that the Phase I Clinical
Trial of Welichem Biotech's anti-psoriasis drug candidate is underway in
Montreal, Quebec. The Clinical Trial is being run by Innovaderm Research Inc.,
which is responsible for the strict protocols, data gathering, and patient
monitoring necessary to comply with applicable standards and procedures.
Innovaderm has been active in medical research since 1999 and has an excellent
reputation for the quality and standards of its research and the care it
offers to subject patients. Innovaderm has a professional staff of doctors,
certified Clinical Research Coordinators, and others within its staff of more
Welichem's Clinical Trial of its topical cream drug candidate, WBI-1001,
is being conducted through six separate cohorts, each consisting of six
patients. All of the patients suffer from mild to moderate psoriasis, symptoms
of which are typical of 80% of all psoriasis sufferers. All patients within a
given cohort will receive the same dosage of WBI-1001's active ingredient on
one side of his/her body; the other side will receive a placebo. Each cohort
will receive a unique dosage of WBI-1001 and will apply the WBI-1001 cream or
a placebo on the affected areas either once or twice a day. Three distinct
dosage strengths will be tested. All patients follow a rigorous reporting and
observation schedule, which includes periodic blood analysis, as well as
topical observation and measurement.
Liren Tang, Ph.D., Welichem's Head of Life Science and the Project
Manager for the Clinical Trial, said:
"We are pleased that our Phase I Clinical Trial is under way. The six
patients in cohort one should all be under treatment by the end of this week,
and their cohort should complete testing after 14 days. We anticipate moving
on to the second cohort right after the first one concludes, and on through
all six clinical trial cohorts. This is an exciting time for Welichem."
All of the Clinical Trials are being governed by Health Canada under the
guidelines of Good Clinical Practices (GCP).
The Company seeks Safe Harbour.
About Welichem Biotech Inc.
Welichem Biotech Inc. is a publicly-traded biotechnology company
developing therapeutic drugs in the fields of autoimmune diseases and cancer.
ON BEHALF OF THE BOARD
York Yingping Guo
President & Chief Executive Officer
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this news
release. This press release contains forward-looking statements that include
our belief as to the potential of our products. Certain risks and
uncertainties such as our ability to successfully commercialize the products
could cause the Company's actual results to differ materially from those in
the forward-looking statements.
For further information:
For further information: Andrew Baren, Investor Relations, Tel.: (604)
432-1703, ext. 224, Email: firstname.lastname@example.org